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The Fetal Basis of Adult Disease: Role of the
Environment
It is recognized that 2–5% of all live-born
infants have a major developmental defect.
Approximately 40% of these defects are
thought to be due to the effect(s) of an adverse
exposure of a genetically predisposed fetus to
intrauterine environmental factors. It is now
clear that in many cases the fetus is more sensi-
tive than the adult to the same environmental
insults. Exposure to environmental agents dur-
ing early development can result in death, struc-
tural malformation, and/or functional alteration
of the embryo or fetus. These toxicant-induced
pathogenic responses are most likely the result
of altered gene expression associated with
altered cell production and cell differentiation
involved in the establishment of cell lineages
leading to the structural and functional charac-
ter of the tissues, organs, and systems that arise
from these lineages.
The NIEHS has a significant program that
addresses the role of developmental exposures
on structural malformations and on functional
alterations whose effects are readily observable
early in development. The purpose of this pro-
gram announcement (PA) with a set-aside of
funds and a Special Emphasis Panel review by
the NIH Center for Scientific Review is to
stimulate research in an important and emerg-
ing area of developmental toxicology: the effects
of in utero exposures that cause permanent
functional changes that are not overtly, grossly
teratogenic, yet that result in increased suscepti-
bility to disease/dysfunction later in the life
span. This PA seeks to encourage the applica-
tion of new high-throughput functional genom-
ic, metabonomic, proteomic, and bioinformatic
technologies to pursue an understanding of
these latent effects of in utero environmental
insult.
The underlying scientific hypothesis behind
the fetal basis of adult disease has been devel-
oped by epidemiologic studies and emphasized
by Dr. David Barker in the United Kingdom.
Most of the supporting studies in this area have
concentrated on grossly altered nutrition in
utero and its striking influence on multiple
aspects of adult health and disease risk. Dr.
Barker has shown that during development,
fetuses respond to severe malnutrition by favor-
ing the metabolic demands of the growing
brain/central nervous system and heart at the
expense of other tissues. The growing
brain/central nervous system and heart tissue
may not, however, escape entirely unscathed.
The long-term consequences of this response
are that the fetus is live-born but is more prone
to diseases later in life.
In support of the Barker hypothesis, epi-
demiologic studies have shown that markers of
malnutrition, such as low birth weight, small
for gestational age, or frank intrauterine growth
retardation (IUGR) strongly predict the subse-
quent occurrence of hypertension, hyperlipi-
demia, insulin resistance, type 2 diabetes
mellitus, ischemic heart disease, breast cancer,
and prostate cancer in adult life. Fetuses that are
clinically malnourished during the first
trimester of development are three times more
likely to be obese as adults. In addition to mal-
nutrition, environmental exposures present dur-
ing in utero development can have profound
influences on fetal growth. Evidence has been
presented in human populations that heavy
exposure to PM10 air pollution containing car-
cinogenic polycyclic aromatic hydrocarbons can
be correlated with increased IUGR with a peak
impact in the earlier portion of the first
trimester—a most vulnerable period of the cell
lineage expansion, differentiation, and cell
interaction events of organogenesis and first
growth.
The concept of fetal programming of struc-
tural–functional formations during develop-
ment has been proposed to explain these
findings, and the resultant research area is
referred to as fetal basis of adult disease, or
FeBAD, research. “Programming” is the term
used to describe lifelong changes in function
that follow a particular event in an earlier peri-
od of the life span. While epidemiologic studies
have identified the phenomenon of metabolic
programming, little is known about the mecha-
nism(s) by which fetal insults lead to altered
programming and to disease later in life.
Emphasis thus far has been on alterations in
nutrition during development with virtually no
focus on the role that exposures to environmen-
tal agents—either alone or in combination with
qualitative alterations in macro- or micronutri-
tion—might have on this phenomenon. There
is evidence that some environmental agents,
especially those with endocrine agonist or
antagonist activity, may alter developmental
programming via alterations in gene expression
or gene imprinting that do not result in malfor-
mations but in functional deficits that do not
become apparent until later in life. In the repro-
ductive tract, the classic example of this phe-
nomenon in the environmental area is the
diethylstilbestrol (DES) story. In humans, in
utero exposure to DES leads to an increase in
vaginal adenocarcinoma around the time of
puberty. In mice, neonatal DES exposure leads
to an increase in uterine adenocarcinoma in
adulthood. While the direct connection has not
been made between in utero programming
changes due to DES and later-life disease, it is
known that DES (in the animal studies) results
in altered gene expression in the uterus that is
irreversible without any noticeable gross alter-
ations in uterine morphology.
Cardiopulmonary diseases in postnatal life
have also been linked to prenatal exposure. The
best-known example is the association between
low birth weight (which is associated with poor
maternal nutrition and perhaps corticosteroid
exposure) and cardiovascular disease (e.g.,
myocardial infarcts), predictors of future cardio-
vascular disease such as hypertension and ather-
osclerosis, and complex metabolic diseases such
as diabetes. In addition, studies have shown that
maternal smoking is associated with deficits in
lung function and with asthma symptoms in
the offspring. Data indicate that these associa-
tions are independent of smoking status after
birth.
Some forms of neurodegenerative disease
may have their origins in in utero exposures. For
example, there is preliminary evidence that a
bacterial stimulus (endotoxin) can produce
cytokines that impair the development of the
mesencephalic dopaminergic systems during
pregnancy. This attenuation of the dopamine
neurons during fetal development leaves the off-
spring with fewer dopaminergic neurons at
birth and at possible increased risk for
Parkinson disease in later life. In a similar vein,
there is preliminary evidence that exposure to
environmental neurotoxicants during dopamin-
ergic development enhances the susceptibility to
accelerated dopaminergic cell death during
aging via the common molecular mechanisms
of the alteration of stress-activated signal trans-
duction pathways, expression of differentiation
transcription factors, survival factors, or pheno-
type marker proteins in the nigral dopaminergic
neurons. Similarly, there is evidence that in
utero exposure to polycyclic biphenyls leads to
altered thyroid function and subsequent learn-
ing disabilities later in life. In all instances, data
are needed to show that the in utero exposures
actually lead to an altered programming at the
molecular level and that the disease/dysfunction
is a direct result, albeit temporally discordant in
its onset and/or progression, of that altered pro-
gramming.
Another promising area for investigation is
how environmental prenatal exposures might
alter immune system programming. The devel-
opment of the immune system, including the
development of the repertoire of reactive lym-
phocytes that will exist in postnatal life, begins
prenatally. Alterations of the fetal immune envi-
ronment might preprogram the highly sensitive
fetal immune system for aberrant immune regu-
lation, leading to a loss of tolerance to self-anti-
gens and resulting in an increased risk for
autoimmune disease. These changes might
manifest in adult life and perhaps only after a
second exposure to related environmental
chemicals. There is evidence, for instance, that
mice exposed prenatally to estrogenic com-
pounds appear to develop normal immune sys-
tems. However, when stimulated with certain
environmental chemicals, they can show an
increased susceptibility to autoimmune disease.
Similarly, there is evidence in humans and
experimental animals that prenatal exposure to
immunosuppressive drugs can lead to immune
alterations in the mature animals.
Based on the epidemiologic data that sup-
port the Barker hypothesis and the preliminary
data showing alterations in gene expression and
imprinting due to in utero exposures to some
environmental agents, we propose that exposure
to certain environmental chemicals as well as
altered nutrition, or in combination with
altered nutrition, will in some situations lead
not to easily identifiable structural malforma-
tions, but instead to alterations in developmen-
tal programming expressed as a permanently
altered gland, organ, or system potential. These
states of altered potential would be a result of
changes in gene expression due to altered
imprinting, and the underlining methylation-
related protein–DNA relationships associated
with chromatin remodeling. These effects may
occur in a time- and tissue-specific manner, and
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such alterations may be irreversible. The end
result is an animal that is sensitized such that it
will be more susceptible to diseases later in life.
The pathophysiology or functional change
that results from the exposures/insult could lead
to 1) the occurrence of a disease that otherwise
would not have happened, 2) an increase in risk
for a disease that would normally be of lower
prevalence, or 3) either an earlier onset of a dis-
ease that would normally have occurred or an
exacerbation of the disease. Finally, the patho-
physiology could have a variable latent period
(depending on the toxicant, time of exposure,
and tissue/organ affected) and potentially trans-
generational effects.
Research approaches relevant to this PA
include the following:
1) To provide a sound mechanistic under-
standing of fetal programming of adult disease,
studies supported by this initiative must involve
whole-animal developmental exposures during
gestation. Applicants can propose studies using
transgenics, model organisms, or rodent models.
For the purpose of this initiative, human studies
(clinical or epidemiologic) are not responsive.
2) Applicants must study an environmental
agent/chemical/stressor to which there is human
exposure and the potential for in utero exposure.
This includes any endocrine-active chemicals or
organic solvents, particulate matter, pesticides,
nutritional supplements, phytochemicals, or
metals. Nutrition alone cannot be used as an in
utero exposure but can be studied in conjunc-
tion with another exposure.
3) Applications must propose studies that
focus on in utero exposures, but additional
exposures at other time points (e.g., exposure
beginning in utero and extending to postnatal
period, exposure in utero followed by adult
exposure) can be included.
4) This initiative requires the use of the new
technologies of gene expression profiling, and
where appropriate, the examination of epigenet-
ics (methylation, imprinting, chromatin remod-
eling).
5) Applications must link in utero exposures
to changes in gene expression that are tissue-
specific and irreversible. These changes in gene
expression will then need to be measured in the
adult and correlated with the disease/dysfunc-
tion studied.
6) A specific adult-onset disease/dysfunc-
tion must be the focus of the application, with
emphasis on the role of in utero exposure and
changes in gene expression in the fetus to the
adult onset or severity of the disease.
Applications that are not focused on a specific
adult disease/dysfunction are not responsive.
For example, applications that focus on in utero
exposures as triggers of diseases of childhood or
puberty are not responsive to this specific
announcement.
7) Applications must focus on one of the
following four emphasis areas: the reproductive
tract, the pulmonocardiovascular system, the
brain/central nervous system, or the
immune/autoimmune system. Diseases of other
tissues or organ systems are not responsive to
this specific announcement. The disease cate-
gories of special interest to the NIEHS with
respect to this initiative include
reproductive/hormonal (fertility; endometriosis;
fibroids; premature menopause; polycystic ovary
syndrome; prostate, ovary, or breast cancer),
cardiopulmonary (heart disease, atherosclerosis,
hypertension, chronic obstructive pulmonary
disease, adult asthma), brain/central nervous
system (neurodegenerative diseases such as
Parkinson disease, Alzheimer disease), and
immune/autoimmune (altered immune respon-
siveness, systemic or tissue-specific autoimmine
diseases of adulthood). It may be possible to
submit applications to this initiative with an
emphasis on other diseases as long as they are
related to one or more of the above noted four
emphasis areas. It should be noted that these are
all adult-onset diseases.
8) Critical areas of expertise that are
required of applicants include developmental
biology/toxicology, disease pathophysiology,
and gene expression profiling, including data
analysis and interpretation of global gene
expression alterations.
9) The National Cancer Institute (NCI) is
interested in funding research aimed at under-
standing the effects of biological, chemical, and
radiologic exposures in utero that cause perma-
nent functional changes resulting in increased
susceptibility to cancer in adult life. The specific
etiologic agents of interest include microorgan-
isms such as herpes virus, HHV8/KSHV,
cytomegalo virus, papilloma virus, polyoma
virus, and bacterial infections such as chlamy-
dia, to name a few. Chemical agents that have
been characterized as carcinogenic or that are
suspected to be carcinogenic in humans—
including polycyclic aromatic hydrocarbons,
nitrosamines, heterocyclic amines, aromatic
amines, DES, and estrogens, as well as metals
and metalloids such as chromium, mercury, and
arsenic—are of interest to the NCI.
Additionally, exposures to radiologic agents
from all externally applied sources as well as
exposure to internally deposited radionuclides
that would result in in utero exposures are of
interest in this context. Studies that link in utero
exposures to such agents that result in perma-
nent alterations in gene expression in tissues of
the reproductive system, the pulmonocardiovas-
cular system, the brain/central nervous system,
or the immune/autoimmune system leading to
or resulting in cancer in those organ sites later
in the adult life of the exposed fetus are sought
by the NCI.
10) The NCI is also interested in funding
research aimed at understanding the conse-
quences of fetal exposure to toxicants, hormone
agonists, or antagonists that alter the expression
or function of the steroid nuclear receptor
superfamily of genes (androgen, estrogen, prog-
esterone, glucocorticoid, vitamin D3, thyroxine)
in normal or cancerous organs of the male and
female reproductive tract and/or immune sys-
tem. The NCI is further interested in the conse-
quences of environmental carcinogen or
tobacco smoke exposure of mice during gesta-
tion that result in long-lasting immune function
deficiencies or inflammatory responses, insofar
as they are related to the development of hema-
tological malignancies or cancers of the repro-
ductive system, the brain/central nervous sys-
tem, and/or the lung. Studies that link fetal
exposure to toxicants or other substances affect-
ing somatic stem cells that later populate organs
such as the mammary gland, the prostate gland,
and the lung, and that have cancer as the end
point, are sought by the NCI.
This PA will use the NIH
exploratory/developmental (R21) award mecha-
nism.The R21 grant award mechanism supports
innovative, high-risk/high-impact research
requiring preliminary testing or development;
exploration of the use of approaches and con-
cepts new to a particular substantive area; and
research and development of data upon which
significant future research may be built.
Applications will be considered high-impact if
they demonstrate the potential for ground-
breaking, precedent-setting significance, and
high-risk if they either lack sufficient prelimi-
nary data to ensure their feasibility or involve
the use of a new model system or technique.
This PA uses just-in-time concepts. It also
uses the modular budgeting format (see
http://grants.nih.gov/grants/funding/
modular/modular.htm). Specifically, if you are
submitting an application with direct costs in
each year of $250,000 or less, use the modular
format. This program does not require cost
sharing as defined in the current NIH Grants
Policy Statement at http://grants.nih.gov/
grants/policy/nihgps_2001/part_i_1.htm. It is
anticipated that approximately $2 million in fis-
cal years 2004 and 2005 will be available to
fund grants in response to this PA. An applicant
for an R21 grant may request a project period
of up to three years and a budget for total direct
costs, including third-party facilities and admin-
istrative costs, not to exceed $100,000 per year.
The deadline for receipt of letters of intent
is 10 July 2004, with 12 August 2004 the dead-
line for receipt of applications. Applications
must be prepared using the PHS 398 research
grant application instructions and forms (rev.
5/2001). The PHS 398 is available at
http://grants.nih.gov/grants/funding/
phs398/phs398.html in an interactive format.
Complete information on this PA is located
online at http://grants.nih.gov/grants/guide/pa-
files/PAR-03-121.html.
Contact: Cindy Lawler, Cellular, Organ,
and Systems Pathobiology Branch, Division of
Extramural Research and Training, NIEHS,
PO Box 12233, MD EC-23, Research Triangle
Park, NC 27709 USA, 919-316-4671, fax:
919-541-5064, e-mail: lawler@niehs.nih.gov.
Reference: PA No. PAR-03-121
Fellowships, Grants, & Awards